Use of rituximab for fulminant and refractory cases of immune checkpoint inhibitor induced myocyte injury clinically presenting with features of myasthenia gravis: a case series.

ABSTRACT:

Background

Immune checkpoint inhibitor-related overlap syndromes are serious and potentially life-threatening complications of immunotherapy. The available evidence is scarce to guide treatment for refractory cases, and patients often experience poorer outcomes.

Case summary

We describe two patients who presented with non-specific symptoms of fatigue and weakness. Both exhibited biomarker evidence of skeletal muscle and myocardial injury, along with clinical features suggestive of myasthenia gravis. The patients rapidly deteriorated, requiring admission to the intensive care unit and eventual intubation due to worsening respiratory status. Despite treatment with high-dose intravenous steroids, there was no significant clinical improvement, although early reductions in biomar

SUBMITTER: Aziz IN 

PROVIDER: S-EPMC12684965 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature